Retrospective study focusing on efficacy and safety of Omidenepag isopropyl

Multicenter retrospective study focusing on efficacy and safety of Omidenepag isopropyl - Multicenter retrospective study of Omidenepag isopropyl

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040040

Enrollment

800

Registered

2020-04-15

Start date

2020-07-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma or Ocular hypertension

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All glaucoma or ocular hypertension patients who were newly treated with Omidenepag isopropyl during observational period

Exclusion criteria

Exclusion criteria: There is no exclusion criteria in this study.

Design outcomes

Primary

Measure	Time frame
IOP-lowering effect	—

Countries

Japan

Contacts

Public ContactEtsuyo Miyamoto

Santen Pharmaceutical Co. Ltd. Japan Medical Affairs

clinical@santen.co.jp06-4802-9603

Outcome results